fatty diacid raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Light points and Combat pages are naturally restored by one unit per turn or by raising the Emotion level of that character, which will restore all Light points. Emotion level is a mechanic that raises whenever a character wins or loses a clash, or when their dice rolls its maximum or minimum value. The group will gain an emotional level-up after their average emotion level reaches a certain point. When the emotion level rises, the player must choose one Abnormality page to apply to a librarian. Abnormality pages come in two colors, green (Awakening) and red (Breakdown), each with its own beneficial effects and drawbacks. The emotion level can rise up to five times per battle, with a total of five Abnormality pages to be picked.
Contraindications to light therapy for seasonal affective disorder include conditions that might render the eyes more vulnerable to phototoxicity, tendency toward mania, photosensitive skin conditions, or use of a photosensitizing herb (such as St. John's wort) or medication. Patients with porphyria should avoid most forms of light therapy. Patients on certain drugs such as methotrexate or chloroquine should use caution with light therapy as there is a chance that these drugs could cause porphyria. Side effects of light therapy for sleep phase disorders include jumpiness or jitteriness, headache, eye irritation and nausea. Some non-depressive physical complaints, such as poor vision and skin rash or irritation, may improve with light therapy.
== Lecture Room Program == In late 2006, a series of her lectures entitled "Yu Dan's Insights into the Analects" (于丹《论语》心得) was broadcast for seven days on China Central Television (CCTV) as part of the Lecture Room (《百家讲坛》) program. The transcript, edited into a book, sold 10,000 copies within the first day of release. Within 40 days, sales exceeded 1.5 million. By September 2007, the book has sold 4.2 million legal copies and an estimated 6 million pirated ones since its publication in December and remains on best-seller lists. It has been published in English under the more literally translated title Confucius from the Heart. In the Spring Festival period of 2007, another series of her lectures "Yu Dan's Insights into Zhuangzi" (于丹《庄子》心得) was broadcast to much acclaim. The transcript "Yu Dan's Notes on Zhuangzi" sold 15,000 copies on its first day of release on March 3. Crowds of people lined up outside the Zhongguancun Xinhua bookstore, waiting as many as eight hours in the rain, just to get Yu Dan's autograph.
Sources: en.wikipedia.org
=== Physical intervention === The most widely used therapeutic intervention is positive airway pressure whereby a breathing machine pumps a controlled stream of air through a mask worn over the nose, mouth, or both. The additional pressure holds open the relaxed muscles. There are several variants:
Restriction digest is the intentional laboratory breaking of DNA strands. It is an enzyme-based treatment used in biotechnology to cut DNA into smaller strands in order to study fragment length differences among individuals or for gene cloning. This method fragments DNA either by the simultaneous cleavage of both strands, or by generation of nicks on each strand of dsDNA to produce dsDNA breaks. Acoustic shearing of the transmission of high-frequency acoustic energy waves delivered to a DNA library. The transducer is bowl shaped so that the waves converge at the target of interest. Nebulization forces DNA through a small hole in a nebulizer unit, which results in the formation of a fine mist that is collected. Fragment size is determined by the pressure of the gas used to push the DNA through the nebulizer, the speed at which the DNA solution passes through the hole, the viscosity of the solution, and the temperature. Sonication, a type of hydrodynamic shearing, subjects DNA to acoustic cavitation and hydrodynamic shearing by exposure to brief periods of sonication, usually resulting in 700bp fragments. For DNA fragmentation, sonication is commonly applied at burst cycles using a probe-type sonicator. Point-sink shearing, a type of hydrodynamic shearing, uses a syringe pump to create hydrodynamic shear forces by pushing a DNA library through a small abrupt contraction. About 90% of fragment lengths fall within a two-fold range. Needle shearing creates shearing forces by passing DNA libraries through small gauge needle.
=== Francis Crick Medal and Lecture === The Francis Crick Medal and Lecture was established in 2003 following an endowment by his former colleague, Sydney Brenner, joint winner of the 2002 Nobel Prize in Physiology and Medicine. The lecture is delivered annually in any field of biological sciences, with preference given to the areas in which Francis Crick himself worked. Importantly, the lectureship is aimed at younger scientists, ideally under 40, or whose career progression corresponds to this age. As of 2019, Crick lectures have been delivered by Julie Ahringer, Dario Alessi, Ewan Birney, Simon Boulton, Jason Chin, Simon Fisher, Matthew Hurles, Gilean McVean, Duncan Odom, Geraint Rees, Sarah Teichmann, M. Madan Babu and Daniel Wolpert.
Sources: en.wikipedia.org
There are over 100 reported pathogenic, or disease-causing, variants in the ASH1L gene. About half of the variants arise de novo, and half are inherited. Of the inherited variants, about half are maternally inherited and half are paternally inherited. Disease-causing variants may be missense, nonsense, or frameshift mutations. The missense mutations are distributed throughout the gene body without localizing to a known functional domain of ASH1L. All affected humans are heterozygous for ASH1L mutations. A single pathogenic copy of ASH1L causes disease, which may be the result of two different genetic mechanisms: haploinsufficiency or dominant negative function. The ClinGen clinical genomics resource states that there is "Sufficient Evidence for Haploinsufficiency" in ASH1L. The most common phenotypes, or symptoms, related to ASH1L mutations are autism spectrum disorder (ASD), epilepsy, intellectual disability, and attention deficit hyperactivity disorder (ADHD). The Simons Foundation Autism Research Initiative (SFARI) gives ASH1L a score of 1.1, indicating that ASH1L is a high confidence autism gene with the best level of evidence linking it to autism.
6 CO2 + 6 H2O → C6H12O6 + 6 O2 For example, large blooms of plankton (free-floating organisms) absorb large amounts of 12C from the oceans. Originally, the 12C was mostly incorporated into the seawater from the atmosphere. If the oceans that the plankton live in are stratified (meaning that there are layers of warm water near the top, and colder water deeper down), then the surface water does not mix very much with the deeper waters, so that when the plankton dies, it sinks and takes away 12C from the surface, leaving the surface layers relatively rich in 13C. Where cold waters well up from the depths (such as in the North Atlantic), the water carries 12C back up with it; when the ocean was less stratified than today, there was much more 12C in the skeletons of surface-dwelling species. Other indicators of past climate include the presence of tropical species and coral growth rings.
Phenylalkylpyrrolidines like PEP, MPEP, prolintane, α-PPP, α-PVP, pyrovalerone, and MDPV Phenylalkylpiperidines like AC927 (phenethylpiperidine), diphenidine, fentanyl, and ifenprodil Tetrahydroisoquinolines (THIQs) like anhalinine, pellotine, lophophorine, DOM-CR, nomifensine, tetrabenazine, and zelandopam Isoquinolines like perafensine, quinisocaine, and tilisolol Dihydroindoles and aminochromes like adrenochrome and adrenolutin 2-Aminoindanes (2-AIs) like 2-aminoindane, MDAI, MMAI, DOM-AI, and Pyr-AI 2-Aminotetralins (2-ATs) like 2-aminotetralin, MDAT, DOM-AT, 8-OH-DPAT, rotigotine, and UH-232 1-Aminomethylindanes (1-AMIs) like 2CB-Ind, AMMI, jimscaline, and bromojimscaline 3-Benzazepines like fenoldopam and lorcaserin Benzocyclobutenes (BCBs) like 2CBCB-NBOMe, S33005, TCB-2, tomscaline, and bromotomscaline 3-Aminochromans like CT-5126, 5-MeO-DPAC, robalzotan, and ebalzotan Benzoxepins like TFMBOX Phenylmethylpyrrolidines (benzylpyrrolidines) like APA-01 (PharmAla-1) 2-Benzylpiperidines and phenidates like 2-benzylpiperidine, methylphenidate, rimiterol, and DMBMPP Phenylcyclopropylamines like tranylcypromine, TMT, and DMCPA 3-Phenylpiperidines (3PIPs) like 3-phenylpiperidine, 3-PPP, OSU-6162 (PNU-96391), LPH-5, LPH-48, 2C-B-3PIP, 2C-B-3PIP-NBOMe, 2C-B-3PIP-POMe, and Z3517967757 (Z7757) 2-Phenylmorpholines like 2-phenylmorpholine, phenmetrazine, manifaxine, radafaxine, flumexadol, oxaflozane, and PF-219,061 Phenyloxazolamines or aminorex analogues like aminorex and pemoline Tricyclic compounds like benzoctamine and dizocilpine Ergolines and lysergamides like ergine (LSA) and LSD Partial ergolines and lysergamides like NDTDI, RU-27849, UCD0179, and UCD0120 Pyridopyrroloquinoxalines like lumateperone, IHCH-7113, IHCH-7086, and ITI-1549 Anthracenes like AMDA and SpAMDA Phenanthrenes like atherosperminine Aporphines like aporphine, apomorphine, glaucine, and nuciferine Others like 6-AB, 2-ADN, 2C-B-PYR, 2C-B-5-hemiFLY-α6 (BNAP), 2CB7 (2C-B-5-hemiFLY-β7), 2CBecca, 2CJP, 2CLisaB, 2CLisaH, 2-naphthylamine, AMMI, GYKI-52895, ivabradine, milnacipran, Org 6582, and ZC-B Some additional cyclized phenethylamines have also been described. Other related families that are not phenethylamines themselves include phenylpiperazines, benzylpiperazines, and 4-phenylpiperidines.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.